The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically ...

Inlexzo is inserted directly into the bladder where it remains for three weeks per treatment cycle for up to 14 cycles, the company said.

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

The U.S. Food and Drug Administration has approved Inlexzo (gemcitabine intravesical system) for the treatment of patients ...

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder cancer. The drug-releasing system TAR-200 has been found to eliminate tumors in ...

Inlexzo, a gemcitabine intravesical system, is approved for BCG-unresponsive NMIBC with carcinoma in situ, offering a new treatment option for patients ineligible for radical cystectomy. The SunRISe-1 ...

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...